Medivir gets 2,6 MUSD following regulatory approval to start clinical trials with the HIV antiviral MIV-150

Medivir gets 2,6 MUSD following regulatory approval to start clinical trials with the HIV antiviral MIV-150 Medivir receives a 2,6 MUSD milestone payment following Chiron's receipt of clearance from the relevant authority to start clinical trials in the UK. Earlier this year Medivir outlicenced the HIV antiviral substance MIV-150 to Chiron Corporation. The agreement gave Chiron the exclusive rights to the global marketing and sales of the HIV drug MIV-150. Medivir received 5 MUSD on signing. If MIV-150 is successful, Medivir would receive up to a total of 35 MUSD upon reaching specified milestones, as well as royalties up to the year 2017, under the Chiron contract. Medivir recently received 3 MUSD as a milestone payment following a decision by Chiron to begin the regulatory process for initiating phase I clinical trials. In total Medivir has now received 10,6 MUSD this year for this project. Huddinge 16 August 1999 Medivir AB (publ) For more information please contact: Jonas Frick, Anna Bernsten, Vice President Business Development and Investor Relations, Medivir AB, phone no +46-8-608 31 05, +46-709-369 069 or e-mail: For more information about Medivir: Medivir is a research and development company which develops new and better substances for the treatment of infectious diseases. The subsidiary company CCS AB develops, manufactures and markets body-care products and pharmaceuticals. The Group consists of the parent company, Medivir AB, the CCS AB subsidiary and UK company CCS (UK) Ltd. ------------------------------------------------------------ Please visit for further information The following files are available for download:

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).